Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Cells of Sclerocorneal Limbus Amplified ex Vivo
NCT ID: NCT01470573
Last Updated: 2012-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2011-11-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Progenitor Autologous Cells
Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
biological replacement corneal surface
the expanded tissue will be applied to patient to replace the damaged ocular surface
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biological replacement corneal surface
the expanded tissue will be applied to patient to replace the damaged ocular surface
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal ophthalmological clinical examination in the opposite eye (biopsied eye)
Exclusion Criteria
* serious disorders in palpebral dynamics
* bilateral limbic insufficiency, immunological, systemic or local illness like toxical epidermic necrosis or pemphigoid
* breastfeeding or pregnancy
* positive serology of HIV, VLTH, HVC, HVB, CMV, Trypanosoma Cruzi or Treponema Pallidum
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundacion Clinic per a la Recerca Biomédica
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Varea
Clinical Research Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ricardo P Casaroli Marano, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Clinic of Barcelona
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Universitario Barraquer
Barcelona, Barcelona, Spain
Instituto de Microcirugía Ocular
Barcelona, Barcelona, Spain
Hospital Clinic of Barcelona
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MeRSO09
Identifier Type: -
Identifier Source: org_study_id